CLM-103

Notably, YYB-103 CAR T cells exhibited effective blood-brain barrier crossing, suggesting compatibility with i.v. administration rather than intracranial injection. Additionally, the high H-score for IL13Rα2 in glioblastoma, especially in conjunction with the poor prognostic markers of wild-type isocitrate dehydrogenase-1 (IDH-1) and unmethylated O -methyl guanine methyl-transferase (MGMT), could be used to determine the eligibility of patients with recurrent glioblastoma for a future clinical trial of YYB-103 CAR T cells.

A number of IL13Rα2-targeting therapies, including CAR-T-targeting IL13Rα2, IL13Rα2-targeted immunotoxins, IL13 expressing virus, anti-IL13Rα2 antibody therapy, and IL13Rα2-targeted tumor vaccine, have been given in clinical trial and have proven to be safe. In this study, we tried to verify the efficacy of newly developed YYB-103, an IL13Rα2-targeted CAR-T, using modified IL13 as an antigen-binding domain, which lowered the binding affinity for IL13Rα1 expressed in normal cells in in vitro and in vivo model, and the possibility of intravenous administration of YYB-103.